Navin Fluorine International (532504) Investor presentation summary

Financial performance highlights

• Q4FY26 sales reached Rs. 937.7 Cr, up 34% YoY, with operating EBITDA at Rs. 321.2 Cr, up 80% YoY and margin at 34.2% (+875 bps YoY).

• FY26 sales totaled Rs. 3,313.9 Cr, up 41% YoY, with operating EBITDA at Rs. 1,081.7 Cr, up 103% YoY and margin at 32.6% (+992 bps YoY).

• Operating PBT for FY26 was Rs. 814.6 Cr (+142% YoY), and PAT was Rs. 663.6 Cr (+130% YoY).

• ROE improved to 20.1% and ROCE to 21.0% in FY26.

• EPS rose to Rs. 130.5 per share in FY26, up 124% YoY.

Business vertical performance

• HPP revenues grew 20% YoY in Q4FY26, driven by improved realizations and higher volumes; additional HFC capacity on track for Q3FY27.

• Specialty Chemicals revenues rose 39% YoY in Q4FY26, with strong order visibility and new product launches; Chemours project and MPP de-bottlenecking progressing.

• CDMO revenues surged 61% YoY in Q4FY26, with commercial supplies started from cGMP4 and a strong pipeline in multiple therapeutic areas.

Capex and growth initiatives

• Ongoing capex includes Rs. 236.5 Cr for HFC, Rs. 75 Cr for MPP, and Rs. 120 Cr for Advanced Materials, all funded by internal accruals or customer contributions.

• Projects target commissioning between Q1FY27 and Q3FY27, with peak revenue potential up to Rs. 825 Cr per annum.